Immuneering Corporation IMRX
3.52 USD -0.19 (-5.12%)
Regular-session close
3.52 0.00 0.00%
After hours · Nov 16, 4:01 PM ET
3.48 Day range 3.78
3.37 52-week range 8.33
- YTD
- -46.50%
- 1 year
- -44.57%
News
seekingalpha.com Immuneering Corporation (IMRX) Discusses Expanded Atebimetinib Development: Pancreatic and Anaplastic Thyroid Cancer Trials Transcript Immuneering Corporation (IMRX) Discusses Expanded Atebimetinib Development: Pancreatic and Anaplastic Thyroid Cancer Trials Transcriptbenzinga.com Immuneering Plans To Initiate Phase 2 Clinical Trial Evaluating Atebimetinib In Combination With Chemotherapy In Patients With Anaplastic Thyroid Cancer - Company plans to evaluate atebimetinib in combination with chemotherapy in a Phase 2 clinical trial in patients with anaplastic thyroid cancer (ATC), a highly aggressive cancer with significant…
benzinga.com Immuneering Enters Into Clinical Trial Collaboration And Supply Agreement To Supply Investigational MEK Inhibitor, Atebimetinib, For Two Astellas-Sponsored Studies Targeting Subset Of Pancreatic Cancer Patients - Collaboration aligns with Immuneering’s expanding strategy to provide a broad population of cancer patients with a wide set of treatment options -- Represents Immuneering’s fourth agreement with a…
globenewswire.com Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer - Company plans to evaluate atebimetinib in combination with chemotherapy in a Phase 2 clinical trial in patients with anaplastic thyroid cancer (ATC), a highly aggressive cancer with significant…
globenewswire.com Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients - Collaboration aligns with Immuneering's expanding strategy to provide a broad population of cancer patients with a wide set of treatment options - - Represents Immuneering's fourth agreement with a…
globenewswire.com Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors - Former TESARO Chief Commercial Officer and Nuvalent board member brings extensive experience in oncology product launches and commercial strategy - - Led commercialization of ZEJULA for ovarian…benzinga.com Immuneering Announces Its Atebimetinib's Data Shows Improvement In Activity Of PD-1 Checkpoint Blockade In RAS-Mutant Colorectal And Lung Cancer Models; Demonstrates 50% Durable Complete Regression In Colorectal Model Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced compelling preclinical data…
